

Supplementary Table 10. Summary of drug repositioning for HCC and supporting evidence

Drug	P-value	Hepatotoxicity	Experimental evidence for HCC	Experimental evidence for other liver diseases	Clinical evidence for HCC	Clinical evidence for other liver diseases
Docetaxel	0.00039	None	18851881	29251522	16645329	
Toziluzumab	0.001835	Exist				
Verteporfin	0.002196	None	33655469			
Calcitriol	0.003071	None	35611989	25712522		33341312
Melphalan	0.005589	None	19709125		34716470	
Lamivudine	0.006131	Exist				
Etonogestrel	0.009841	None				
Latanoprost	0.010654	None				
Furosemide	0.011742	None				32833292
Metoprolol	0.011973	None	30008820			
Thrombin	0.013886	None	20890897	25138021		
Somatostatin	0.015647	None	19478472; 19590186	18173562; 15949036	21804474	26129925; 34873228
Disulfiram	0.020463	Exist				
Cyclosporine	0.020905	Exist				
Thalidomide	0.028647	None	16313753		22346253	

The numbers shown in the table represent PubMed Identifier (PMID) numbers, which provide evidence for the foundational research and clinical studies supporting the therapeutic effects of the respective drugs.
 HCC, hepatocellular carcinoma.